ClinicalTrials.gov
public full text
Public Domain
Safety and Efficacy of Ranibizumab for Diabetic Macular Edema
The primary objective of the study is to assess the ocular and systemic adverse events of ranibizumab (Lucentis)for DME (diabetic macular edema) following previous treatment with intravitreal bevacizumab (Avastin).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)#28509
- Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration#1140061
- To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema#903436
- Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy#1260942
- A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO#1164669
Record · ID 1231392
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive